|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Establishing proof of concept:Platelet-rich plasma and bone marrow aspirate concentrate may improve cartilage repair following surgical treatment for osteochondral lesions of the talus显示文摘Osteochondral lesions of the talus are common injuries in the athletic patient. They present a challenging clinical problem as cartilage has a poor potential for healing. Current surgical treatments consist of reparative(microfracture) or replacement(autologous osteochondral graft) strategies and demonstrate good clinical outcomes at the short and medium term follow-up. Radiological findings and second-look arthroscopy however, indicate possible poor cartilage repair with evidence of fibrous infill and fissuring of the regenerative tissue following microfracture. Longer-term follow-up echoes these findings as it demonstrates a decline in clinical outcome. The nature of the cartilage repair that occurs for an osteochondral graft to become integrated with the native surround tissue is also of concern. Studies have shown evidence of poor cartilage integration,with chondrocyte death at the periphery of the graft, possibly causing cyst formation due to synovial fluid ingress. Biological adjuncts, in the form of platelet-rich plasma(PRP) and bone marrow aspirate concentrate(BMAC), have been investigated with regard to their potential in improving cartilage repair in both in vitro and in vitro settings. The in vitro literature indicates that these biological adjuncts may increase chondrocyte proliferation as well as synthetic capability, while limiting the catabolic effects of an inflammatory joint environment. These findings have been extrapolated to in vitro animal models, with results showing that both PRP and BMAC improve cartilage repair. The basic science literature therefore establishes the proof of concept that biological adjuncts may improve cartilage repair when used in conjunction with reparative and replacement treatment strategies for osteochondral lesions of the talus. | Niall A Smyth Christopher D Murawski Amgad M Haleem Charles P Hannon Ian Savage-Elliott John G Kennedy | 2012 | World Journal of Orthopedics2012，3，7： | 8 |
| 2 | Platelet-rich plasma increases transforming growth factor-beta1 expression at graft-host interface following autologous osteochondral transplantation in a rabbit model显示文摘AIM: To explore the effect of platelet-rich plasma on protein expression patterns of transforming growth factor-beta1(TGF-β1) in cartilage following autologous osteochondral transplantation(AOT) in a rabbit knee cartilage defect model.METHODS: Twelve New Zealand white rabbits received bilateral AOT. In each rabbit, one knee was randomized to receive an autologous platelet rich plasma(PRP) injection and the contralateral knee received saline injection. Rabbits were euthanized at 3, 6 and 12 wk post-operatively. Articular cartilage sections were stained with TGF-β1 antibody. Histological regions of interest(ROI)(left, right and center of the autologous grafts interfaces) were evaluated using Meta Morph. Percentage of chondrocytes positive for TGF-β1 was then assessed.RESULTS: Percentage of chondrocytes positive for TGF-β1 was higher in PRP treated knees for selected ROIs(left; P = 0.03, center; P = 0.05) compared to control and was also higher in the PRP group at each post-operative time point(P = 6.6 × 10^(-4), 3.1 × 10^(-4) and 7.3 × 10^(-3) for 3, 6 and 12 wk, respectively). TGF-β1 expression was higher in chondrocytes of PRP-treated knees(36% ± 29% vs 15% ± 18%)(P = 1.8 × 10^(-6)) overall for each post-operative time point and ROI. CONCLUSION: Articular cartilage of rabbits treated with AOT and PRP exhibit increased TGF-β1 expression compared to those treated with AOT and saline. Our findings suggest that adjunctive PRP may increase TGF-β1 expression, which may play a role in the chondrogenic effect of PRP in vivo. | Lorraine A Boakye Keir A Ross John M Pinski Niall A Smyth Amgad M Haleem Charles P Hannon Lisa A Fortier John G Kennedy | 2015 | World Journal of Orthopedics2015，6，11： | 7 |
| 3 | Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab显示文摘AIM:To investigate the safety and efficacy of adding bevacizumab to first-line chemotherapy in metastatic colorectal cancer patients with peritoneal disease.METHODS:We compared rates of gastrointestinal perforation in patients with metastatic colorectal cancer and peritoneal disease receiving first-line chemotherapy with and without bevacizumab in three distinct cohorts:(1) the AGITG MAX trial(Phase Ⅲ randomised clinical trial comparing capecitabine vs capecitabine and bevacizumab vs capecitabine,bevacizumab and mitomycin C);(2) the prospective Treatment of Recurrent and Advanced Colorectal Cancer(TRACC) registry(any first-line regimen ± bevacizumab);and(3) two cancer centres in New South Wales,Australia [Macarthur Cancer Therapy Centre and Liverpool Cancer Therapy Centre(NSWCC) from January 2005 to Decenber 2012,(any first-line regimen ± bevacizumab).For the AGITG MAX trial capecitabine was compared to the other two arms(capecitabine/bevacizumab and capecitabine/bevacizumab/mitomycin C).In the AGITG MAX trial and the TRACC registry rates of gastrointestinal perforation were also collected in patients who did not have peritoneal metastases.Secondary endpoints included progression-free survival,chemotherapy duration,and overall survival.Time-toevent outcomes were estimated using the Kaplan-Meier method and compared using the log-rank test.RESULTS:Eighty-four MAX,179 TRACC and 69 NSWCC patients had peritoneal disease.There were no gastrointestinal perforations recorded in either the MAX subgroup or the NSWCC cohorts.Of the patients without peritoneal disease in the MAX trial,4/300(1.3%) in the bevacizumab arms had gastrointestinal perforations compared to 1/123(0.8%) in the capecitabine alone arm.In the TRACC registry 3/126(2.4%) patients who had received bevacizumab had a gastrointestinal perforation compared to 1/53(1.9%) in the chemotherapy alone arm.In a further analysis of patients without peritoneal metastases in the TRACC registry,the rate of gastrointestinal perforations was 9/369(2.4%) in the chemotherapy/bevacizumab group and 5/177(2.8%) in the chemotherapy alone group.The addition of bevacizumab to chemotherapy was associated with improved progression-free survival in all three cohorts:MAX 6.9 m vs 4.9 m,HR = 0.64(95%CI:0.42-1.02);P = 0.063;TRACC 9.1 m vs 5.5 m,HR = 0.61(95%CI:0.37-0.86);P = 0.009;NSWCC 8.7 m vs 6.8 m,HR = 0.75(95%CI:0.43-1.32);P = 0.32.Chemotherapy duration was similar across the groups.CONCLUSION:Patients with peritoneal disease do not appear to have an increased risk of gastrointestinal perforations when receiving first-line therapy with bevacizumab compared to systemic therapy alone. | Aflah Roohullah Hui-Li Wong Katrin M Sjoquist Peter Gibbs Kathryn Field Ben Tran Jeremy Shapiro Joe Mckendrick Desmond Yip Louise Nott Val Gebski Weng Ng Wei Chua Timothy Price Niall Tebbutt Lorraine Chantrill | 2015 | World Journal of Gastroenterology2015，21，17： | 3 |
| 4 | Cost benefit analysis of the use of tranexamic acid in primary lower limb arthroplasty: A retrospective cohort study显示文摘AIM: To examine the cost benefit conferred by the perioperative administration of intravenous tranexamic acid(TXA) in lower limb arthroplasty.METHODS: This study evaluates the use of TXA in 200 consecutive lower limb arthroplasties performed in a single surgeon series. The initial 100 patients(control group) underwent surgery without perioperative administration of TXA while the subsequent 100 patients(TXA group) all received 1 g TXA at the time of induction of anaesthesia. Pre- and post-operative haemoglobin, platelet count, haematocrit, the use of blood product post-operatively, length of stay were examined. A financial analysis of both groups was then undertaken. RESULTS: The mean age of patients in both groups was 63 ± 13 years. There were no significant differences between groups in terms of gender(P = 0.47), proportion of total hip replacement to total knee replacement(P = 0.25) or pre-operative haemoglobin(P = 0.43). In the control group, the transfusion rate was 22%. In the TXA group, the transfusion rate dropped to 2%(P < 0.001). The mean post-operative haemoglobin was 10.82 ± 1.55g/dL in the control group vs 11.33 ± 1.27 g/dL in the TXA group(P = 0.01). The total cost of transfused blood products was €11055 and €603 respectively. The mean length of stay in the control group was 6.53 ± 5.93 d vs 5.47 ± 4.26 d in the TXA group(P = 0.15) leading to an estimated financial saving of €114586. There was one pulmonary embolus in the control group and one deep venous thrombosis in the TXA group.CONCLUSION: Intravenous TXA reduces blood loss in lower limb arthroplasty. This leads to lower transfusion rates, shorter length of stay in hospital and significant financial savings. | Niall P McGoldrick Eabhann M O'Connor Nikos Davarinos Rose Galvin John F Quinlan | 2015 | World Journal of Orthopedics2015，6，11： | 3 |
| 5 | Quality of life issues in men undergoing androgen deprivation therapy: a review显示文摘雄激素剥夺治疗(ADT ) 是为治疗前列腺癌症(PCa ) 的一种必要治疗选择。为神经质的治疗的角色开始被限制为人与变形、不能实行,局部地先进的疾病。现在,它为外科和放射疗法被扩大了到 neoadjuvant 或辅助治疗,为在外科或放射以后的生物化学的恶化,并且为非变形的疾病弄平同样主要的治疗。对待的百分之五十个 PCa 病人将在某点收到 ADT。关于与更普遍的 ADT 使用联系的不利效果和费用正在种担心。生活(QoL ) 的质量上的不利效果,当人们是剥夺雄激素的时,包括物理、社会、心理的健康,可能可观。这评论在下列区域检验 QoL 问题:身体女性化,性变化,关系变化,认知、感情方面的症状,疲劳,睡觉骚乱,消沉和物理效果。推进建议因为减少这些改变的治疗学的途径被建议。 | Rowan G Casey Niall M Corcoran S Larry Goldenberg | 2012 | Asian Journal of Andrology2012，14，2： | 2 |
| 6 | Ma- ternal separation as a model of brain-gut axis dysfunction 显示文摘 | Siobhain M O' Mahony Niall P Hyland Timothy G | 2011 | Psychopharmacology2011，214，1： | 1 |
| 7 | Sequences of Pitultary and Placental Lactogenic and Growth Hormones:Evolution from a Primordial Peptide by Gene Reduplication显示文摘 | NIALL H D HOGAN M L SAUER R | 1971 | Proc Natl Acad Sci USA1971，68，： | 1 |
| 8 | The effects of epidermal growth factor on wound healing in mice 显示文摘 | NIALL M RYAN GB O'BRIEN BM | 1982 | J Surg Res1982，33，： | 1 |
| 9 | Impacts of man-made landscape features on numbers of estuarine wa- terbirds at low tide 显示文摘 | NIALL H K B MICHAEL J S A ANDREW J M | 2002 | Environmental Management2002，30，6： | 1 |
| 10 | Towards an integrated global framework to assess the impacts of land use and management change on soil carbon: current capability and future vision显示文摘 | Pete Smith Christian A. Davies Stephen Ogle Giuliana Zanchi Jessica Bellarby Neil Bird Robert M. Boddey Niall P. M c Namara David Powlson Annette Cowie Meine Noordwijk Sarah C. Davis Daniel DE B. Richter Len Kryzanowski Mark T. Wijk Judith Stuart Akira Ki | 2012 | Glob Change Biol2012，，7： | 1 |
| 11 | Effect of intravenous testosterone on myocardial ischemia in men with coronary artery disease显示文摘 | Alan W Niall M | 2002 | Am Heart J2002，143，： | 1 |
| 12 | Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy显示文摘 | Perry M Elliott Juan R Gimeno Blanes Niall G Mahon Jan D Poloniecki William J McKenna | 2001 | The Lancet2001，，9254： | 1 |
| 13 | Sudden death in hypertrophic cardiomyopathy: identification of high risk patients显示文摘 | Perry M Elliott Jan Poloniecki Shaughan Dickie Sanjay Sharma Lorenzo Monserrat Amanda Varnava Niall G Mahon William J McKenna | 2000 | Journal of the American College of Cardiology2000，，7： | 1 |
| 14 | Glucose-potassium-insulin infusions in the management of post-stroke hyperglycaemia: the UK Glucose Insulin in Stroke Trial (GIST-UK)显示文摘 | Christopher S Gray Anthony J Hildreth Peter A Sandercock Janice E O'Connell Donna E Johnston Niall EF Cartlidge John M Bamford Oliver F James K George MM Alberti | 2007 | Lancet Neurology2007，，5： | 1 |
| 15 | A novel technique fordilating difficult malignant biliary strictures during therapeuticERCP显示文摘 | Niall R van Someren M Benson MJ | 1996 | Gastrointest Endosc1996，43，5： | 1 |
| 16 | Plating of humeral shaft fractures has the pendulum swung back 显示文摘 | Niall DM O ' M ahony J McElwain JP | 2004 | Injury2004，35，6： | 1 |
| 17 | Modeling misperception in games显示文摘 | WANG Mu-hong KEITH W H NIALL M | 1998 | Behavioral Science1998，33，2： | 1 |
| 18 | Sudden death in hypertrophic cardiomyopathy: identification of high risk patients显示文摘 | Perry M Elliott Jan Poloniecki Shaughan Dickie Sanjay Sharma Lorenzo Monserrat Amanda Varnava Niall G Mahon William J McKenna | 2000 | Journal of the American College of Cardiology2000，，7： | 1 |
| 19 | An overview of CO2 capture technol- ogies显示文摘 | Niall M D Nick F Antoine B | 2010 | Energy Environ Sci2010，103，： | 1 |
| 20 | Prospective Familial Assessment in Dilated Cardiomyopathy: Cardiac Autoantibodies Predict Disease Development in Asymptomatic Relatives显示文摘 | Alida L.P. Caforio Niall G. Mahon M Kamran Baig Francesco Tona Ross T. Murphy Perry M. Elliott William J. McKenna | 2007 | Circulation2007，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员